Skip to main content
Literatur
2.
Zurück zum Zitat Kluge R, et al. Current status of FDG-PET/CT in the treatment setting of Hodgkin’s lymphoma in childhood and adolescence. Clin Transl Imaging. 2015;3:309–19.CrossRef Kluge R, et al. Current status of FDG-PET/CT in the treatment setting of Hodgkin’s lymphoma in childhood and adolescence. Clin Transl Imaging. 2015;3:309–19.CrossRef
3.
Zurück zum Zitat Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456–63.CrossRefPubMed Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456–63.CrossRefPubMed
5.
Zurück zum Zitat Kobe C, Goergen H, Baues C, et al. Outcome-based interpretation of early interim PET in advanced stage Hodgkin lymphoma. Blood. 2018;132(21):2273–9.CrossRefPubMed Kobe C, Goergen H, Baues C, et al. Outcome-based interpretation of early interim PET in advanced stage Hodgkin lymphoma. Blood. 2018;132(21):2273–9.CrossRefPubMed
Metadaten
Titel
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion
verfasst von
Sara Pacella
Publikationsdatum
12.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05990-8

Weitere Artikel der Ausgabe 1/2022

European Journal of Nuclear Medicine and Molecular Imaging 1/2022 Zur Ausgabe